Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 2027

Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 2027.

Clinical holds and partial pauses on cell therapy programmes have followed a familiar script in this space: a safety signal triggers a voluntary or regulator-imposed pause, enrollment freezes across affected arms, and the programme sits in limbo until the sponsor isolates root cause, whether the issue lies in the construct itself, the manufacturing process, lymphodepletion, or patient selection. The distinction that matters is between a product-intrinsic problem, which tends to be terminal or programme-narrowing, and a process or protocol problem, which has historically been resolvable with amended monitoring and resumed dosing. Identifying the cause and flagging a restart path puts this in the latter camp, though a restart window stretching well out implies remediation work, protocol amendments, and regulatory back-and-forth rather than a quick lift. Sponsors with prior CAR-T experience have form for eventually returning paused studies to enrollment, but timelines on these have a record of slipping, so the guidance functions as an intention rather than a commitment. The follow-ons are whether the disclosed cause implicates the broader platform or is confined to the paused indication, any regulatory commentary on the restart conditions, and how competing programmes in the same target space fill the enrollment gap in the interim. As a single-spokesperson statement without the underlying data, the signal is directional.